Stockwinners Market Radar for February 14, 2025 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:50 EST Cyngn trading halted, news pending

19:50 EST 5E Advanced Materials trading halted, news pending

19:50 EST Magic Empire Global Ltd trading halted, news pending

17:53 EST TechPrecision names Alexander Shen as interim principal financial officer - TechPrecision announced that the Board of Directors of the company appointed Alexander Shen, the company's CEO, to serve as the interim principal financial officer and principal accounting officer ofthe company, effective at 5:30 p.m. February 14, after the previously disclosed resignation of Richard Roomberg, the company's former CFO, took effect. Shen will serve in these capacities while the company searches for a replacement for Roomberg. The company has reported separately in Form 12b-25 that it is unable to file its Quarterly Report on Form 10-Q for the period ended December 31, 2024 within the prescribed time period. Alexander Shen stated, "For FY25 Q3, ending December 31, 2024, the company is targeting Friday, Mar 7, 2025 to file. Filing on March 7, 2025 will result in 21 days late. Resource drain from acquisition activity is the single major contributor to TechPrecision's late SEC filings. Timely reporting is one of our fundamentals; we have been taking steps to achieve and consistently maintain compliance to this requirement."

17:36 EST Algonquin Power names Brian Chin as interim CFO - Algonquin Power CEO Chris Huskilson announced that Vice President of Investor Relations Brian Chin will assume the role of Interim CFO, effective March 7. The announcement follows an earlier announcement of the pending departure of current CFO, Darren Myers, who is leaving to pursue another opportunity. Algonquin has engaged a nationally recognized search firm to commence a search to identify a permanent CFO.

17:16 EST Oncolytics receives noncompliance notification from Nasdaq - Oncolytics announced that it received a delinquency notification letter from Nasdaq indicating that the company is not currently in compliance with the minimum bid price requirement set forth in Nasdaq's Listing Rules for continued listing on the Nasdaq Capital Market, as the closing bid price for the company's ordinary shares listed on Nasdaq was below $1.00 per share for 30 consecutive business days. The notice provides that the company has a period of 180 calendar days from the date of the Notice, or until August 12 to regain compliance with the minimum bid price requirement.

17:02 EST TuanChe to change name to Token Cat - TuanChe announce that effective on or around February 28, the company will change its name to Token Cat Limited. The company's ADSs will continue trading on the Nasdaq Capital Market under the trading symbol (TC), and the CUSIP number shall remain unchanged.

17:00 EST Third Point buys Capital One, cuts Microsoft in Q4 - Third Point disclosed in an SEC filing its holdings as of December 31, 2024. The fund's new buys during the fourth quarter included, by size of position, Thermo Fisher (TMO), Capital One (COF), Fortive (FTV), Workday (WDAY), and Discover (DFS). Third Point exited a number of positions during the quarter, including by size of previous position Bath & Body Works (BBWI), Apple (AAPL), Roper (ROP), Amphenol (APH), and CVS (CVS). The fund increased its stake in a number of positions, including by size of previous position Telephone and Data Systems (TDS), Flutter (FLUT), LPL Financial (LPL), Tesla (TSLA), and Meta (META). Third Point reduced its stake in a number of holdings, including by size of previous position Vistra (VST), Microsoft (MSFT), Danaher (DHR), Cinemark (CNK), and Apollo Global (APO). The fund's top holdings as of December 31, in order of size, were PG&E (PCG), Amazon (AMZN), Danaher, Meta, and TSMC (TSM).

16:55 EST Soros buys Arthur J. Gallagher, boosts Accenture in Q4 - George Soros' Soros Fund Management disclosed in an SEC filing its holdings as of December 31, 2024. The fund's new buys during the fourth quarter included, by size of position, iShares Russell 2000 ETF (IWM), Arthur J. Gallagher (AJG), SPDR S&P 500 ETF Trust (SPY), iShares iBoxx $ Investment Grand Corporate Bond ETF (LQD), and KraneShares CSI China Internet ETF (KWEB). Soros exited a number of positions during the quarter, including by size of previous position, iShares Core S&P 500 ETF (IVV), EchoStar (SATS), Global Payments (GPN), Merck (MRK), and Vulcan Materials (VMC). The fund increased its stake in several holdings, including by size of previous position Alphabet Class A (GOOGL), Salesforce (CRM), Smurfit WestRock (SW), Accenture (ACN), and Amazon (AMZN). Soros reduced its stake in a number of positions, including by size of previous position Financial Select Sector SPDR Fund (XLF), Alibaba (BABA), Jacobs (J), iShares MSCI Emerging Markets ex China ETF (EMXC), and Aurora Innovation (AUR). The fund's top holdings as of December 31, in order of size, were Smurfit Westrock, Alphabet Class A, AstraZeneca (AZN), iShares Russell 2000 ETF, and GFL Environmental (GFL).

16:47 EST Icahn boosts CVR Partners, cuts Illumina in Q4 - Carl Icahn's Icahn Capital disclosed in an SEC filing its holdings as of December 31, 2024. The fund increased its stakes in two holdings, including by size of previous position CVR Partners (UAN) and Icahn Enterprises (IEP). Icahn reduced its stake in three holdings, namely Southwest Gas (SWX), Illumina (ILMN), and Centuri Holdings (CTRI). The fund's top holdings as of December 31, in order of size, were Icahn Enterprises, CVR Energy (CVI), Southwest Gas, International Flavors (IFF), and CVR Partners.

16:36 EST Trian boosts stakes in Solventum, U-Haul and Wendy's, cuts Allstate stake - Nelson Peltz's Trian Fund Management disclosed in an SEC filing its holdings as of December 31, 2024. Trian increased its stake in a number of holdings, including by size of previous position, Solventum (SOLV), U-Haul (UHAL), and Wendy's (WEN). Trian reduced its stake in two holdings, including by size of previous position, Allstate (ALL) and Ferguson (FERG). Trian's top holdings as of December 31, 2024, in order of size, were Janus Henderson (JHG), GE Aerospace (GE), Solventum, Wendy's and Invesco (IVZ).

16:33 EST OFS Credit reports January NAV per share between $6.95-$7.05 - OFS Credit announced the following net asset value estimate as of January 31. Management's unaudited estimate of the range of our NAV per share of our common stock as of January 31 is between $6.95 and $7.05.

16:33 EST MDU Resources plans to invest in Badger Wind Farm - MDU Resources Group is pleased to announce that its subsidiary, Montana-Dakota Utilities Co., has signed a purchase agreement to acquire a 49% ownership interest in the Badger Wind Farm. This acquisition represents 122.5 MW of the project's total 250 MW generation capacity. The purchase agreement is contingent on regulatory approval from the North Dakota Public Service Commission. This strategic investment is part of MDU Resources' five-year capital expenditure plan. The estimated cost for MDU to purchase this stake is $294M.

16:27 EST ConnectOne Bancorp, First of Long Island shareholders approve proposed merger - ConnectOne Bancorp (CNOB) and First of Long Island (FLIC) announced that at separate special meetings the shareholders of both companies approved proposals relating to the pending merger of ConnectOne and First of Long Island. Closing of the transaction is expected to occur in the second quarter of 2025, subject to the receipt of regulatory approval and other customary closing conditions. Upon completion of the transaction, the combined company will operate under the ConnectOne brand, and will have approximately $14B in total assets, $11B in total deposits, and $11B in total loans.

16:25 EST Quetta Acquisition Corp trading halted, news pending

16:16 EST CoStar Group acquires Ag-Analytics, terms not disclosed - CoStar Group announced that it has acquired agricultural data company Ag-Analytics. The strategic acquisition of Ag-Analytics will specifically enhance CoStar Group's Land.com platform, marking the company's extension into the agricultural land sector. This acquisition will strengthen the data capabilities for farmland, forestland, recreational, and other rural properties through Ag-Analytics' cutting-edge AcreValue platform, unlocking new opportunities for land and ag-focused institutional investors and lenders.

16:12 EST Ackman's Pershing Square buys Brookfield, cuts Chipotle in Q4 - Bill Ackman's Pershing Square Capital disclosed in an SEC filing its holdings as of December 31, 2024. The fund's three new buys during the fourth quarter included, by size of position, Brookfield (BAM), Seaport Entertainment (SEG), and Nike (NKE). Pershing decreased its stake in two holdings during the period, including by size of previous position Hilton Worldwide (HLT) and Chipotle (CMG). The fund's top holdings as of December 31, in order of size, were Brookfield, Restaurant Brands (QSR), Chipotle, Howard Hughes (HHC), and Alphabet Class C (GOOG).

16:09 EST Starboard Value buys Pfizer, exits Humana in Q4 - Jeffrey Smith's Starboard Value disclosed in an SEC filing its holdings as of December 31, 2024. The fund's new buys during the fourth quarter included, by size of position, Kenvue (KVUE), Pfizer (PFE), Healthcare Realty Trust (HR), iShares Core S&P Mid-Cap ETF (IJH), and Riot Platforms (RIOT). Starboard exited two positions during the quarter, including iShares Russell 2000 Value ETF (IWM) and Humana (HUM). The fund increased its stake in Match Group (MTCH), Alight (ALIT), and Algonquin Power (AQN), and reduced its stake in Salesforce (CRM), Autodesk (ADSK), Wix.com (WIX), Fortrea (FTRE), and Green Dot (GDOT). Starboard's top holdings as of December 31, in order of size, were GoDaddy (GDDY), Gen Digital (GEN), Match Group, Kenvue, and Pfizer.

16:01 EST Entero Therapeutics names Richard Paolone as interim CEO - Entero Therapeutics announced that the board of directors has appointed Richard Paolone as the interim CEO of the company. Richard Paolone is a Toronto-based securities lawyer with extensive experience in corporate finance, securities law, and mergers and acquisitions.

15:26 EST FDA approves Sanofi biosimilar product for treatment of diabetes - The U.S. Food and Drug Administration approved Merilog as biosimilar to Novolog for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. "Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA. As a rapid-acting insulin, Merilog helps to lower mealtime blood sugar spikes to improve control of blood sugar in people with diabetes. The approval is for both a 3 milliliter single-patient-use prefilled pen and a 10 milliliter multiple-dose vial. Merilog is the third insulin biosimilar product approved by the FDA and joins the two long-acting insulin biosimilar products approved in 2021 by the FDA," the agency stated. The FDA granted approval of Merilog to Sanofi-Aventis U.S. Reference Link

14:35 EST UroGen announces results from subgroup analyses of ENVISION trial - UroGen Pharma announced results from the subgroup analyses of the pivotal ENVISION study evaluating the impact of tumor burden and focality on the response to UGN-102, an investigational drug in development for treatment of LG-IR-NMIBC. Analyses of pre-specified subgroups showed comparable CR rates and DOR patterns across different levels of tumor burden and number of tumors at baseline in patients treated with UGN-102. The poster presentation titled, Impact of Tumor Burden or Focality in Recurrent Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer on Response to Treatment with UGN-102: A Substudy of the Phase 3 ENVISION Trial was presented today at ASCO GU 2025. "We are encouraged by these results, which highlight the potential of UGN-102 to provide durable responses in patients with recurrent LG-IR-NMIBC," said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. "These pre-specified subgroup analyses further strengthen the growing body of evidence supporting UGN-102 as a treatment option for patients dealing with the challenges of disease recurrence and the need for repeated surgeries."

14:11 EST Tiger Global buys PDD, exits ZoomInfo in Q4 - Chase Coleman's Tiger Global disclosed in an SEC filing its holdings as of December 31, 2024. The fund's new buys during the fourth quarter included, by size of position, Zscaler (ZS), PDD (PDD), CoStar (CSGP), Veeva (VEEV), and Standard Aero (SARO). Tiger exited its position in three names, including ZoomInfo (ZI), Toast (TOST), and StoneCo (STNE). The fund increased its stake in Spotify (SPOT), Reddit (RDDT), Eli Lilly (LLY), Sherwin-Williams (SHW), and Coupang (CPNG), and reduced its stake in UnitedHealth (UNH), Nubank (NU), and Apollo Global (APO). Tiger Global's top holdings as of December 31, in order of size, were Meta (META), Microsoft (MSFT), Apollo, Alphabet Class A (GOOGL), and Sea Ltd (SE).

13:20 EST Dell Technologies up 6% to $116.35 after Bloomberg report

13:02 EST Baker Hughes reports U.S. rig count up 2 to 588 rigs - Baker Hughes reports that the U.S. rig count is up 2 from last week to 588 with oil rigs up 1 to 481, gas rigs up 1 to 101 and miscellaneous rigs up unchanged at 6. The U.S. Rig Count is down 33 rigs from last year's count of 621 with oil rigs down 16, gas rigs down 20 and miscellaneous up 3. The U.S. Offshore Rig Count is unchanged at 14, down 5 year-over-year. The Canada Rig Count is down 4 from last week to 245, with oil rigs down 3 to 174, gas rigs down 1 to 71 and miscellaneous rigs unchanged at 0. The Canada Rig Count is up 11 rigs from last year's count of 234 with oil rigs up 30, gas rigs down 19 and miscellaneous rigs unchanged.

13:01 EST Baker Hughes reports U.S. rig count up 2 to 588 rigs

12:36 EST WANG & LEE GROUP Inc trading resumes

12:31 EST WANG & LEE GROUP Inc trading halted, volatility trading pause

12:12 EST Bellevue Life Sciences Acquisition Corp trading resumes

12:02 EST LP Building increases quarterly dividend to 28c from 26c per share - LP Building Solutions declared an increased quarterly cash dividend to common stockholders of 28c per share, up 8% from its previous 26c per share quarterly dividend. The dividend will be payable on March 13, to stockholders of record as of February 27.

12:00 EST CAE rises 16.3% - CAE is up 16.3%, or $3.84 to $27.35.

12:00 EST Seabridge Gold falls -13.2% - Seabridge Gold is down -13.2%, or -$1.76 to $11.57.

12:00 EST Informatica falls -30.3% - Informatica is down -30.3%, or -$7.62 to $17.55.

11:54 EST Cooperman's Omega Advisors buys KBR, cuts Fiserv in Q4 - Leon Cooperman's Omega Advisors disclosed in an SEC filing its holdings as of December 31, 2024. The fund's new buys during the fourth quarter included, by size of position, KBR (KBR), Las Vegas Sands (LVS), iShares MSCI Eafe ETF (EFA), iShares Core MSCI Europe ETF (IEUR), and iShares MSCI Japan ETF (EWJ). Omega exited two positions during the quarter, including by size of previous position DT Midstream (DTM) and CommScope (COMM). The fund increased its stakes in Finance of America (FOA), Elevance (ELV), Ashland (ASH), SunOpta (STKL), and Fidelis Insurance (FIHL), and reduced its stakes in Regal Rexnord (RRX), Lithia & Driveway (LAD), ADT (ADT), Fiserv (FI), and Arbor Realty Trust (ABR). Omega's top holdings as of December 31, in order of size, were Mr Cooper (COOP), Energy Transfer (ET), Vertiv (VRT), Apollo Global (APO), and WillScot (WSC).

11:21 EST TEN Holdings Inc trading halted, volatility trading pause

11:04 EST INLIF Ltd trading resumes

10:44 EST INLIF Ltd trading halted, volatility trading pause

10:00 EST DaVita falls -14.7% - DaVita is down -14.7%, or -$26.10 to $150.96.

10:00 EST Informatica falls -33.0% - Informatica is down -33.0%, or -$8.30 to $16.87.

10:00 EST TreeHouse rises 22.2% - TreeHouse is up 22.2%, or $7.37 to $40.63.

09:57 EST ConnectM regains compliance with Nasdaq listing rule - ConnectM Technology previously received a notice from the Staff of the Listing Qualifications Department of Nasdaq stating that because the Company had not filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024, it no longer complies with Nasdaq Listing Rule 5250(c)(1) for continued listing, which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission. ConnectM today announced that on January 31, the Staff notified ConnectM that, based on the Company's December 16, filing of the Third Quarter 10-Q, Staff has determined that the Company complies with the Rule. Accordingly, the matter is now closed.

09:48 EST Zhihu rises 14.6% - Zhihu is up 14.6%, or 67c to $5.27.

09:48 EST Nu Skin rises 49.7% - Nu Skin is up 49.7%, or $3.19 to $9.61.

09:47 EST DaVita falls -13.7% - DaVita is down -13.7%, or -$24.32 to $152.75.

09:46 EST NanoVibronix completes acquisition of ENvue Medical - NanoVibronix announced the completion of the acquisition of ENvue Medical Holdings. The company said, "This strategic transaction will combine the strengths of both companies, creating a platform for growth and expanded market reach in the medical device sector. The Company believes that the Acquisition will strengthen the combined company's market position in enteral feeding technology and therapeutic medical devices, as ENvue's proprietary technology aligns with the Company's commitment to patient safety and advanced medical solutions and the combined company is expected to benefit from a broader commercial platform, enhanced distribution and operational efficiencies." The Acquisition of ENvue was structured as a stock-for-stock transaction pursuant to which all of ENvue's outstanding equity interests were exchanged based on a fixed exchange ratio for consideration as a combination of 1,734,995 shares of the Company common stock, which such number of shares represented no more than 19.9% of the outstanding shares of Company common stock as of immediately before the effective time of the Acquisition, and 57,720 shares of Series X Non-Voting Convertible Preferred Stock. Subject to Company stockholder approval, each share of Series X Preferred Stock will automatically convert into 1,000 shares of common stock, subject to certain beneficial ownership limitations set by each holder. After giving effect to Acquisition and pursuant to the terms and conditions of the merger agreement governing the Acquisition, the holders of the outstanding equity of ENvue immediately prior to the effective time of the first merger own 19.9% of the common stock of the Company and 85.0% of the outstanding equity of the Company immediately following the First Effective Time, which following stockholder approval will allow the Series X Preferred Stock to convert to common stock of the Company, which may result in the holders of ENvue holding 85% of the common stock of the Company, and the holders of our outstanding equity immediately prior to the First Effective Time holding 80.1% of the common stock of the Company and 15.0% of the outstanding equity of the Company immediately following the First Effective Time, which following stockholder approval will allow the Series X Preferred Stock to convert to common stock of the Company which may result in our holders holding 15% of common stock of the Company. Following the consummation of the Acquisition, a successor-in-interest of ENvue will become a wholly-owned subsidiary of the Company. The Acquisition was approved by the Board of Directors of Company and the Board of Directors and stockholders of ENvue and was consummated on February 14, 2025. Concurrently with the completion of the Acquisition, the Company consummated a private placement investment with an institutional investor, pursuant to which the Company sold in a private placement a senior convertible debenture having an aggregate principal amount of $500,000. Following the receipt of stockholder approval, the Debenture is convertible, in whole or in part, into shares of the Company's common stock, at the option of the holder, at the initial conversion price of $0.4446, which is subject to customary anti-dilution adjustments, and which such conversion price shall not be lower than the floor price of $0.08892.

09:44 EST Dominari Holdings Inc trading resumes

09:40 EST Moderna trading resumes

09:39 EST Dominari Holdings Inc trading halted, volatility trading pause

09:36 EST Alliance Entertainment Holding Corp trading halted, volatility trading pause

09:35 EST eGain trading resumes

09:35 EST Picocela Inc trading resumes

09:32 EST WeRide jumps 135% to $40.41 after Nvidia disclosed stake at end of 2024

09:30 EST eGain trading halted, volatility trading pause

09:30 EST PowerUp Acquisition Corp trading halted, volatility trading pause

09:05 EST Brera Holdings highlights financial efficiency of Juve Stabia - The company said, "Brera Holdings reports that its newest portfolio club, S.S. Juve Stabia, has emerged as the most financially efficient club in Serie B in terms of cost per point. Juve Stabia, also known as 'The Second Team of Naples,'is currently positioned in a playoff-qualifying sixth place in the Serie B standings. With an annual wage bill of EUR 5.63M and 36 points to date this season, Juve Stabia boasts an impressive wage cost per point of just EUR 156,389-the lowest in the league. This financial efficiency underscores Juve Stabia's strong financial discipline, especially when compared to other clubs in Serie B - according to Capology data. In contrast, higher-spending clubs such as 17th-placed Salernitana and 14th-placed Sampdoria rank at the bottom of the cost per point index at EUR 715,714 and EUR 710,000 per point, respectively. On February 12th, Brera Holdings announced the third closing in its multi-step transaction to acquire a majority stake in Juve Stabia. Following this closing, Brera Holdings now holds a 38.46% equity ownership interest in the club."

09:04 EST Artelo Biosciences announces new data on ART12.11 - Artelo Biosciences announced nonclinical results on ART12.11, its proprietary cocrystal composition of cannabidiol and tetramethylpyrazine. The findings were presented by Professor Saoirse O'Sullivan, Vice President of Translational Science at Artelo Biosciences, at the International Medical Cannabis Conference, held February 13-14, 2025, at the University of Bern, Switzerland. Professor O'Sullivan's presentation, "A Cannabidiol Cocrystal Tablet Has Comparable Pharmacokinetics to Epidiolex," highlighted results from canine studies evaluating Artelo's oral solid formulations of ART12.11 against the liquid formulation of Epidiolex, the only FDA-approved CBD therapy. The studies showed that two different tablet formulations of ART12.11 achieved CBD and metabolite exposure levels similar or greater to the equivalent dose of Epidiolex, supporting the potential of ART12.11 as an alternative formulation of CBD.

09:03 EST IN8bio presented Phase 1 data on INB-100 at 2025 TCT - IN8bio presented Phase 1 data on its allogeneic gamma-delta T cell therapy, INB-100, at the 2025 Transplantation & Cellular Therapy, TCT, Meetings in Hawaii. The data, previously announced, reinforce INB-100's potential to significantly reduce post-transplant relapse in high-risk acute myeloid leukemia, AML, patients, positioning this gamma-delta T cell therapy as a promising approach in hematologic oncology. The latest findings demonstrate that INB-100 continues to deliver long-term remissions, with no AML patient relapses observed to date with a median follow-up of 20.1 months. The 1-year progression-free survival rate across all leukemia patients stands at 90.9%, and 1-year overall survival is 100%, outperforming real-world historical controls. These data demonstrate that results for INB-100 do not appear to be due to imbalances in patient selection criteria, the performance of the individual clinical centers or driven by specific transplant or lymphodepletion protocols. These data underscore INB-100's potential to reshape post-transplant care by leveraging gamma-delta T cells to enable sustained cancer cell surveillance and long-term remissions.

09:00 EST Jet.AI Inc trading resumes

08:40 EST Winnebago appoints Steve Speich as SVP, enterprise operations - Winnebago Industries (WGO) announced that Steve Speich will be joining the organization as SVP, enterprise operations, effective March 3, 2025. Speich most recently served as global director of manufacturing for Deere's (DE) Intelligent Solutions group, with ownership of end-to-end factory operations, inclusive of manufacturing and supply chain responsibilities. In his new role, Speich will oversee Winnebago Industries' manufacturing capabilities, strategic sourcing program, business excellence initiatives, product quality management, and employee health, safety, and security efforts. Speich's appointment follows the transition of Chris West, former SVP of enterprise operations, who was recently named president of the company's Winnebago-branded motorhome business.

08:37 EST flyExclusive to acquire Jet.AI aviation business in all-stock transaction - flyExclusive (FLYX) has entered a definitive agreement to acquire the aviation business of Jet.AI (JTAI). flyExclusive will acquire the business in conjunction with Jet.AI's focus on being a pure-play AI solutions company. The transaction will occur following Jet.AI's spin of the business into a new company, which would then be acquired by flyExclusive. Jet.AI shareholders will retain their Jet.AI stock and receive new Class A common shares in flyExclusive as part of the transaction. The business combination is contingent upon the closing conditions outlined in the agreement. The business combination is structured as an all-stock transaction, spinning off Jet.AI's charter business assets into the SpinCo, which in turn will be acquired by flyExclusive. The business combination consideration will be in the form of a number of fully paid and non-assessable shares of Class A common stock of flyExclusive equal to the quotient of the purchase price, divided by the average volume-weighted average price of flyExclusive's stock for the thirty trading days immediately prior to the effective date. Jet.AI shareholders will retain their Jet.AI stock while receiving new Class A common shares in flyExclusive to account for the portion of the aviation business being spun-off. The purchase price shall be determined based on Jet.AI's net cash multiplied by the applicable premium percentage. Net Cash of at least $12M is a condition to closing the business combination and will consist of the company's cash on hand subtracting any cash net working capital requirement mutually agreed upon, and transaction costs triggered by the closing of the business combination. To satisfy closing conditions and to meet the company's ongoing financing requirements, Jet.AI has signed a $50M non-binding term sheet with Hexstone Capital on economic terms substantially similar to those of its existing $16.5M arrangement with Ionic Ventures. The applicable premium percentage paid for the aviation business will be between 115% and 120% equivalent to a dollar value today contemplated in the range of $12M to $22M, depending on the net cash value at the close of transaction. The transaction is expected to close in the second quarter of 2025, subject to various closing conditions, including but not limited to Jet.AI financing, regulatory review, and shareholder approval.

08:34 EST LQR House announces marketing partnership with Loca Loka Tequila - LQR House announced its latest strategic marketing partnership with Loca Loka Tequila brand. This collaboration aims to leverage LQR House's proprietary marketing expertise to increase brand awareness and boost sales for Loca Loka Tequila on its online alcohol marketplace, CWSpirits.com.

08:33 EST BrilliA establishes cooperation framework with Maison Lejaby - BrilliA established a cooperation framework with the French luxury lingerie brand Maison Lejaby, with an anticipated supply value of up to EUR 10M based on projected needs. Under this arrangement, BrilliA will supply intimate apparel products-including bras, panties, bodysuits, sleepwear, and swimwear-aligned with Maison Lejaby's evolving requirements. Maison Lejaby, currently sold in France, Spain, Italy, the UK, Israel, and Russia, has announced plans to expand into additional global markets within the next three years. In addition, BrilliA has also secured an opportunity to introduce its own premium luxury DIANA brand in Europe no later than 2027.

08:28 EST SoundHound, Serve Robotics, Nano-X lower after filing shows no Nvidia holdings - Shares of SoundHound AI (SOUN), Serve Robotics (SERV) and Nano-X Imaging (NNOX) are all lower in premarket trading after Nvidia (NVDA) filed a 13F with the SEC that indicates that the chipmaking giant exited its stakes in the companies.

08:25 EST Jet.AI Inc trading halted, news pending

08:13 EST Phoenix Motor regains compliance with Nasdaq listing - Phoenix Motor has received confirmation from The Nasdaq Stock Market that the Company has regained compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission. On November 20, 2024, Nasdaq Staff notified the Company that it was not in compliance with the Rule due to a delay in filing its periodic financial reports. However, following the Company's filing of its Form 10-Q for the period ended September 30, 2024, on February 12, 2025, Nasdaq has confirmed that the Company has now met the requirements under the Rule. Accordingly, this matter is now closed.

08:10 EST Outlook Therapeutics announces upcoming anticipated milestones - Resubmission of the ONS-5010 BLA targeted for Q1 CY2025; Initial commercial launches in Germany and the UK planned to commence in Q2 CY2025; and Potential for US FDA approval of ONS-5010 in Q3 CY2025.

08:09 EST PetVivo signs exclusive sales, marketing agreement with VetStem - PetVivo Holdings has entered into an Exclusive License and Supply Agreement with VetStem to commercialize VetStem's innovative allogeneic orthobiologic products, PrecisePRP canine and PrecisePRP equine. "This is a game changer for veterinarians and their ability to treat their patients with PRP", said Mike Eldred, PetVivo Board Member. "This innovative, and FDA reviewed product, will be a great addition to Spryng with OsteoCushion(TM) technology, and supports our strategy to be the leader in veterinary medical devices and regenerative medicine."

08:07 EST Oryzon Genomics announces publication of Phase IIa REIMAGINE results - Oryzon Genomics announced that the final results of the Phase IIa REIMAGINE study, which evaluated the safety and efficacy of vafidemstat on aggression in adult patients with borderline personality disorder, attention-deficit/hyperactivity disorder, and autistic spectrum disorder, were published online in Psychiatry and Clinical Neurosciences. A summary of the final data from this study had been previously released at the 2020 European Psychiatry Association annual meeting.REIMAGINE was a Phase IIa, single-center, open-label, one-arm basket trial that evaluated the safety and efficacy of vafidemstat, Oryzon's brain-penetrant, orally available LSD1 inhibitor, on aggression in adult patients with BPD, ADHD, and ASD. In the trial, participants received 1.2 mg/day of vafidemstat for 8weeks. As reported in the publication, the study showed that vafidemstat was safe and well-tolerated and elicited significant and consistent reduction in agitation/aggression in patients with BPD, ADHD, and ASD. Vafidemstat also produced a significant improvement in nonaggressive features and overall disease indicators in these populations.Based on the results from the REIMAGINE study, Oryzon continued the development of vafidemstat in psychiatric indications and conducted the Phase IIb PORTICO trial in BPD. In this trial, vafidemstat demonstrated nominal statistical significance in reducing agitation and aggression on the STAXI-2 Trait Anger scale and in improving overall BPD disease on the BEST scale, and also reached statistical significance on the Global Statistic Test. Following positive feedback from the End-of-Phase II meeting with the U.S. Food and Drug Administration, Oryzon initiated preparations for Phase III and is currently preparing the full protocol for the PORTICO-2 Phase III trial for submission to the FDA. Vafidemstat is also being evaluated in the Phase IIb EVOLUTION trial in negative symptoms of schizophrenia.

08:05 EST GCL Global announces acquisition of 20% equity interests of NEKCOM - GCL Global announced the acquisition of 20% equity interests of NEKCOM, a video game developer, and the global publishing rights of NEKCOM's upcoming game, "Showa American Story." GCL acquired 20% equity interests of NEKCOM in the form of Series B Preferred Stock pursuant to a Series B Preferred Stock Purchase Agreement dated November 20, 2024, by and among GCL Global Limited, a wholly owned subsidiary of GCL, NEKCOM and other parties named therein. Effective at the close of the transaction on December 18, 2024, Jacky Choo See Wee, GCL's Group Chairman, became a Director on NEKCOM's Board of Directors. GCL's publishing arm, 4Divinity, has obtained the global publishing rights for NEKCOM's upcoming game, "Showa American Story." The new role-playing game is an enthusiastic love letter to 80's pop culture featuring a string of cult classic B-Movies. Playing as 19-year-old stuntwoman, Chouko, gamers will join her on a journey of truth and revenge across a version of North America where the United States is an unofficial colony of Japan. The game is currently expected to be released in 2025.

08:03 EST Daxor announces case series published in JACC - Daxor announces a case series published in JACC: Case Reports has identified a distinct phenotype in heart failure patients characterized by expanded blood volume overload and elevated red blood cells, opening new avenues for targeted treatment through therapeutic phlebotomy. In the study, researchers evaluated 179 advanced heart failure patients using Daxor's blood volume analysis, BVA. Through this analysis, they identified thirty-six patients and closely monitored four heart failure cases over a 12-month period, helping to detect an under-recognized condition. Key Takeaways: BVA detects critical volume issues missed by standard blood tests that drive patient outcomes; This condition affects 700,000-1,400,000 US heart failure patients; Patients with this phenotype show worse clinical outcomes than typical heart failure cases; Higher stroke and blood clot risks pose additional clinical challenges for these patients if untreated; Therapeutic phlebotomy guided by BVA showed significant symptom improvement with zero hospitalizations/deaths over 12 months.

07:53 EST TC Energy files 2024 annual disclosure documents - TC Energy filed with Canadian securities authorities: Audited Consolidated Financial Statements for the year ended Dec. 31, 2024 with related Management's Discussion and Analysis; and The Company's Annual Information Form for the year ended Dec. 31, 2024. In addition, TC Energy filed its Form 40-F for the year ended Dec. 31, 2024 with the United States Securities and Exchange Commission.

07:42 EST AbbVie names Robert Michael as chairman of board of directors - AbbVie announced that its board of directors has unanimously elected CEO Robert Michael to assume the additional position of chairman, effective July 1. He will succeed Richard Gonzalez, who formerly served as AbbVie's CEO and has been chairman since the company's formation in 2013.

07:35 EST 180 Degree Capital says combination is in 'best interest of all' shareholders - 180 Degree Capital issued a Q4 2024 Shareholder Letter, which read in part, "We are incredibly proud of our recent announcement of the signing of a definitive agreement for 180 Degree Capital to enter into a business combination with Mount Logan Capital...We expect to file a registration statement and joint proxy statement/prospectus with the Securities and Exchange Commission soon. This document will give us the opportunity to speak with our shareholders more extensively about the proposed Business Combination and the process that led to our Board's unanimous approval of this strategically important transaction. This proposed transaction is not the end of 180 Degree Capital. We believe it is the logical next step in our evolution. It is also an opportunity that is not afforded commonly to closed-end funds, particularly since we believe most have limited differentiation. We believe there are clear reasons why 180 Degree Capital has this truly unique opportunity to combine with an asset manager and to transition to an operating company...Math is math. Our public market investment strategy over the history of 180 Degree Capital outperformed our comparable peers and indices. It is fair to ask why our stock price has not followed. We believe it is largely because of the significant negative impact of the private portfolio that we inherited, and the discounts disproportionately applied to closed-end funds of our size. Hence, I come back to our proposed Business Combination with Mount Logan, and what we believe it can do to potentially unlock value for 180 Degree Capital shareholders when we are no longer constrained by the market dynamics ascribed to closed-end funds. We will let our upcoming registration statement and included joint proxy statement/prospectus provide the truth to our shareholders regarding how and why our Board unanimously approved this proposed Business Combination. In the meantime, our work over the prior eight years set up 180 Degree Capital for this next phase of what we believe will be long-term shareholder value creation. We realize our lack of scale has caused our expense ratio to be too high. We believe we have uncovered a unique solution for that and other growth-limiting issues with our proposed Business Combination. Our Board and management team firmly believe that this Business Combination is in the best interest of all of our shareholders. We could not be more excited about the potential for future value creation as a result of combining with Mount Logan, and we look forward to discussing this proposed combination with all of you and prospective future shareholders of the combined entity."

07:33 EST Owens Corning to sell glass reinforcements business to Praana Group for $755M - Owens Corning and Praana Group announced that they have signed a definitive agreement for the sale of Owens Corning's glass reinforcements business to Praana Group at an enterprise value of $755M. This sale is a part of Owens Corning's strategic plan to reshape the company to focus on residential and commercial building products in North America and Europe. The business generated revenue of approximately $1.1B in 2024 and has approximately 4,000 employees across a global footprint that includes 18 operations in 12 countries. The sale will complete Owens Corning's review of strategic alternatives for the business announced in early 2024. The transaction is expected to close in 2025 and is subject to customary regulatory approvals and other conditions. Owens Corning will retain the other businesses within its composites segment. These include the company's vertically integrated glass nonwovens business that supports its Roofing segment and other building products customers, along with its structural lumber business. Going forward, these businesses will operate within Owens Corning's Roofing segment. Owens Corning's two glass melting plants in the U.S., which provide glass fibers to make nonwovens products, will operate and be integrated within its Insulation segment.

07:11 EST Howard Hughes announces updated land, density guidelines in Ward Village - Ward Village has opened the makai phase of Victoria Ward Park, the community's first SITES-certified park and the initial phase of a two-part development plan for enhanced public green space. The opening of Victoria Ward Park Makai is part of Ward Village's broader master plan to create a sustainable, connected community, and coincides with amended HCDA Mauka Area Rules effective January 2025 that establish updated guidelines for smart growth in the district mauka of Ala Moana Boulevard, inclusive of undeveloped Ward Village properties. The new guidelines represent the potential for an estimated 2.5 - 3.5 million gross square feet of future redevelopment, adding to the community of Ward Village and creating synergies with broader Kaka'ako. The updated rules emphasize transit-oriented development incentive zones, supporting a balanced mix of homes, public spaces, restaurants, and retail experiences to bring greater public benefit to the neighborhood.

07:08 EST NFI Group announces MTA adding 265 zero-emission buses to its fleet - NFI Group announced New York's Metropolitan Transit Authority, MTA, is adding 265 zero-emission buses to its fleet. This option order, part of a contract between New Flyer and the MTA signed in Q1 2024, allows for the purchase of 193 Xcelsior CHARGE NG 40-foot buses and 72 Xcelsior CHARGE NG 60-foot buses.

07:06 EST Creative Medical announces mid-term follow-up study data from StemSpine study - Creative Medical Technology announced mid-term follow-up data from its StemSpine pilot study utilizing its AlloStem cells for the treatment of chronic lower back pain. The pilot study demonstrated a substantial reduction in opioid dependency and significant improvements in pain levels and functional mobility. Notably, over 90% of patients reported no opioid use for pain management three years post-procedure, with an 80% persistent reduction in pain scores and a greater than 60% improvement in Oswestry Disability Index scores. Only one patient required reintervention at the three-year follow-up mark, and no serious adverse events were reported, reinforcing the favorable safety profile of the StemSpine procedure.

07:05 EST Cibus announces important update to rice gene editing conversion rates - Cibus issued a correction relating to the rice conversion rates previously disclosed in its January 16, 2025 press release. The Company has concluded that the gene editing conversion rates of 10-25% in Rice have not been reconfirmed based upon subsequent experiments and high variability in the conversion rate data. Cibus is continuing to advance its oligonucleotide directed mutagenesis, ODM, editing technologies to drive improved editing conversion rates across its developed traits across its crops of interest.

06:38 EST Nebius, Applied Digital listed among Nvidia holdings in filing - In a regulatory filing with the SEC, Nvidia (NVDA) disclosed holdings as of the end of 2024 that included Applied Digital (APLD), Arm Holdings (ARM), Nebius Group (NBIS), Recursion Pharmaceuticals (RXRX) and WeRide (WRD). In a separate filing, Nvidia disclosed that it no longer holds any shares of Serve Robotics (SERV). Reference Link

06:24 EST NatWest Group sees 2027 RoTE greater than 15%

06:07 EST 180 Degree Capital reports NAV of $4.64 as of December 31, 2024 - "We were pleased with our performance in Q4 2024 relative to the majority of our public market comparable indices," said Kevin Rendino, Chief Executive Officer of 180 Degree Capital. "While our full year performance was disappointing, Q1 2025 has thus far continued and exceeded our strong performance exiting 2024. Our gross total return of +205% from inception through the end of 2024 continues to compare favorably to the +69% total return for the Russell Microcap Index."

06:03 EST Fortis announces five-year capital plan of C$26B - Fortis continues to enhance shareholder value through the execution of its capital plan, the balance and strength of its diversified portfolio of regulated utility businesses, and growth opportunities within and proximate to its service territories. The corporation's C$26B five-year capital plan is expected to increase midyear rate base from C$39B in 2024 to C$53B by 2029, translating into a five-year compound annual growth rate of 6.5%.